{
    "startDate": "2017-01-01",
    "endDate": "2017-12-31",
    "year": "2017",
    "quarter": "FY",
    "symbol": "AKCA",
    "data": {
        "bs": [
            {
                "label": "Cash and cash equivalents",
                "concept": "CashAndCashEquivalentsAtCarryingValue",
                "unit": "usd",
                "value": 58367000
            },
            {
                "label": "Short-term investments",
                "concept": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
                "unit": "usd",
                "value": 201763000
            },
            {
                "label": "Contracts receivable",
                "concept": "ReceivablesLongTermContractsOrPrograms",
                "unit": "usd",
                "value": 5413000
            },
            {
                "label": "Other current assets",
                "concept": "OtherAssetsCurrent",
                "unit": "usd",
                "value": 1302000
            },
            {
                "label": "Current assets:",
                "concept": "AssetsCurrent",
                "unit": "usd",
                "value": 266845000
            },
            {
                "label": "Property, plant and equipment, net",
                "concept": "PropertyPlantAndEquipmentNet",
                "unit": "usd",
                "value": 77000
            },
            {
                "label": "Licenses, net",
                "concept": "FiniteLivedIntangibleAssetsNet",
                "unit": "usd",
                "value": 1221000
            },
            {
                "label": "Deposits and other assets",
                "concept": "OtherAssetsNoncurrent",
                "unit": "usd",
                "value": 661000
            },
            {
                "label": "Amortization expense",
                "concept": "Assets",
                "unit": "usd",
                "value": 268804000
            },
            {
                "label": "Accounts payable",
                "concept": "AccountsPayableCurrent",
                "unit": "usd",
                "value": 2381000
            },
            {
                "label": "Payable to Ionis Pharmaceuticals, Inc.",
                "concept": "DueToRelatedPartiesCurrent",
                "unit": "usd",
                "value": 14365000
            },
            {
                "label": "Accrued compensation",
                "concept": "EmployeeRelatedLiabilitiesCurrent",
                "unit": "usd",
                "value": 4083000
            },
            {
                "label": "Accrued liabilities",
                "concept": "AccruedLiabilitiesCurrent",
                "unit": "usd",
                "value": 7570000
            },
            {
                "label": "Current portion of deferred revenue",
                "concept": "DeferredRevenueCurrent",
                "unit": "usd",
                "value": 50579000
            },
            {
                "label": "Other current liabilities",
                "concept": "OtherLiabilitiesCurrent",
                "unit": "usd",
                "value": 1875000
            },
            {
                "label": "Accrued liabilities",
                "concept": "LiabilitiesCurrent",
                "unit": "usd",
                "value": 80853000
            },
            {
                "label": "Long-term portion of deferred rent",
                "concept": "DeferredRentCreditNoncurrent",
                "unit": "usd",
                "value": 12000
            },
            {
                "label": "Long-term portion of deferred revenue",
                "concept": "DeferredRevenueNoncurrent",
                "unit": "usd",
                "value": 8306000
            },
            {
                "label": "Accrued liabilities",
                "concept": "Liabilities",
                "unit": "usd",
                "value": 89171000
            },
            {
                "label": "Series A convertible preferred stock, $0.001 par value; no and 28,884,540 shares authorized, no and 28,884,540 shares issued and outstanding at December 31, 2017 and 2016, respectively; aggregate liquidation value of $0 and $610,304 as of December 31, 2017 and 2016, respectively",
                "concept": "PreferredStockValue",
                "unit": "usd",
                "value": 0
            },
            {
                "label": "Common stock, $0.001 par value; 100,000,000 shares authorized, 66,541,629 and no shares issued and outstanding at December 31, 2017 and 2016, respectively",
                "concept": "CommonStockValue",
                "unit": "usd",
                "value": 67000
            },
            {
                "label": "Additional paid-in capital",
                "concept": "AdditionalPaidInCapitalCommonStock",
                "unit": "usd",
                "value": 464430000
            },
            {
                "label": "Accumulated other comprehensive loss",
                "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
                "unit": "usd",
                "value": -451000
            },
            {
                "label": "Accumulated deficit",
                "concept": "RetainedEarningsAccumulatedDeficit",
                "unit": "usd",
                "value": -284413000
            },
            {
                "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": 179633000
            },
            {
                "label": "Total liabilities and stockholders' equity (deficit)",
                "concept": "LiabilitiesAndStockholdersEquity",
                "unit": "usd",
                "value": 268804000
            }
        ],
        "cf": [
            {
                "label": "Adjustments to reconcile net loss to net cash used in operating activities:",
                "concept": "NetIncomeLoss",
                "unit": "usd",
                "value": -109751000
            },
            {
                "label": "Depreciation",
                "concept": "Depreciation",
                "unit": "usd",
                "value": 108000
            },
            {
                "label": "Amortization expense",
                "concept": "AmortizationOfIntangibleAssets",
                "unit": "usd",
                "value": 120000
            },
            {
                "label": "Amortization of premium on investments, net",
                "concept": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
                "unit": "usd",
                "value": -499000
            },
            {
                "label": "Stock-based compensation expense",
                "concept": "ShareBasedCompensation",
                "unit": "usd",
                "value": 17539000
            },
            {
                "label": "Other current and long-term assets",
                "concept": "IncreaseDecreaseInOtherOperatingAssets",
                "unit": "usd",
                "value": 1761000
            },
            {
                "label": "Accounts payable",
                "concept": "IncreaseDecreaseInAccountsPayable",
                "unit": "usd",
                "value": 1905000
            },
            {
                "label": "Payable to Ionis Pharmaceuticals, Inc.",
                "concept": "IncreaseDecreaseInDueToRelatedPartiesCurrent",
                "unit": "usd",
                "value": -43385000
            },
            {
                "label": "Accrued compensation",
                "concept": "IncreaseDecreaseInOtherEmployeeRelatedLiabilities",
                "unit": "usd",
                "value": 1578000
            },
            {
                "label": "Accrued liabilities",
                "concept": "IncreaseDecreaseInAccruedLiabilities",
                "unit": "usd",
                "value": 6587000
            },
            {
                "label": "Income taxes payable",
                "concept": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
                "unit": "usd",
                "value": 1789000
            },
            {
                "label": "Deferred revenue",
                "concept": "IncreaseDecreaseInDeferredRevenue",
                "unit": "usd",
                "value": 58885000
            },
            {
                "label": "Operating activities:",
                "concept": "NetCashProvidedByUsedInOperatingActivities",
                "unit": "usd",
                "value": -36190000
            },
            {
                "label": "Purchases of short-term investments",
                "concept": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
                "unit": "usd",
                "value": 301377000
            },
            {
                "label": "Proceeds from sale of short-term investments",
                "concept": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
                "unit": "usd",
                "value": 98778000
            },
            {
                "label": "Purchases of property, plant and equipment",
                "concept": "PaymentsToAcquirePropertyPlantAndEquipment",
                "unit": "usd",
                "value": 9000
            },
            {
                "label": "Investing activities:",
                "concept": "NetCashProvidedByUsedInInvestingActivities",
                "unit": "usd",
                "value": -202608000
            },
            {
                "label": "Proceeds from issuance of Series A convertible preferred stock to Ionis Pharmaceuticals, Inc.",
                "concept": "ProceedsFromIssuanceOfConvertiblePreferredStock",
                "unit": "usd",
                "value": 0
            },
            {
                "label": "Investment by Ionis",
                "concept": "ProceedsFromContributionsFromParent",
                "unit": "usd",
                "value": 0
            },
            {
                "label": "Proceeds from issuance of common stock, net of underwriters' discounts",
                "concept": "ProceedsFromIssuanceOrSaleOfEquity",
                "unit": "usd",
                "value": 135438000
            },
            {
                "label": "Proceeds from sale of common stock to Novartis in a private placement",
                "concept": "ProceedsFromIssuanceOfPrivatePlacement",
                "unit": "usd",
                "value": 50000000
            },
            {
                "label": "Proceeds from line of credit from Ionis Pharmaceuticals, Inc.",
                "concept": "ProceedsFromRepaymentsOfRelatedPartyDebt",
                "unit": "usd",
                "value": 106000000
            },
            {
                "label": "Offering costs paid",
                "concept": "PaymentsOfStockIssuanceCosts",
                "unit": "usd",
                "value": 2037000
            },
            {
                "label": "Net cash provided by (used in) financing activities",
                "concept": "NetCashProvidedByUsedInFinancingActivities",
                "unit": "usd",
                "value": 289401000
            },
            {
                "label": "Effect of exchange rates on cash",
                "concept": "EffectOfExchangeRateOnCashAndCashEquivalents",
                "unit": "usd",
                "value": -93000
            },
            {
                "label": "Net increase (decrease) in cash and cash equivalents",
                "concept": "CashAndCashEquivalentsPeriodIncreaseDecrease",
                "unit": "usd",
                "value": 50510000
            },
            {
                "label": "Conversion of preferred stock to common stock upon initial public offering",
                "concept": "ConversionOfStockAmountConverted1",
                "unit": "usd",
                "value": 100000000
            },
            {
                "label": "Conversion of line of credit from Ionis Pharmaceuticals, Inc. into common stock",
                "concept": "StockIssued1",
                "unit": "usd",
                "value": 107731000
            }
        ],
        "ic": [
            {
                "label": "Total revenue",
                "concept": "Revenues",
                "unit": "usd",
                "value": 55209000
            },
            {
                "label": "Research and development",
                "concept": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
                "unit": "usd",
                "value": 126890000
            },
            {
                "label": "General and Administrative Expenses [Member]",
                "concept": "GeneralAndAdministrativeExpense",
                "unit": "usd",
                "value": 36981000
            },
            {
                "label": "Expenses:",
                "concept": "OperatingExpenses",
                "unit": "usd",
                "value": 163871000
            },
            {
                "label": "Loss from operations",
                "concept": "OperatingIncomeLoss",
                "unit": "usd",
                "value": -108662000
            },
            {
                "label": "Investment income",
                "concept": "InvestmentIncomeNet",
                "unit": "usd",
                "value": 1813000
            },
            {
                "label": "Interest expense",
                "concept": "InterestExpenseRelatedParty",
                "unit": "usd",
                "value": 1731000
            },
            {
                "label": "Other income",
                "concept": "OtherNonoperatingIncome",
                "unit": "usd",
                "value": 104000
            },
            {
                "label": "Loss before income tax expense",
                "concept": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
                "unit": "usd",
                "value": -108476000
            },
            {
                "label": "Total current",
                "concept": "IncomeTaxExpenseBenefit",
                "unit": "usd",
                "value": 1275000
            },
            {
                "label": "Adjustments to reconcile net loss to net cash used in operating activities:",
                "concept": "NetIncomeLoss",
                "unit": "usd",
                "value": -109751000
            },
            {
                "label": "Unrealized gains (losses) on investments, net of tax",
                "concept": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
                "unit": "usd",
                "value": -337000
            },
            {
                "label": "Currency translation adjustment",
                "concept": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
                "unit": "usd",
                "value": -93000
            },
            {
                "label": "Comprehensive loss",
                "concept": "ComprehensiveIncomeNetOfTax",
                "unit": "usd",
                "value": -110181000
            }
        ]
    }
}